Akheel Syed
Overview
Explore the profile of Akheel Syed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heald A, Mannan F, Wiltshire R, Ghaffari P, Waheed U, Zdravkovic D, et al.
Diabetes Ther
. 2024 Jul;
15(9):2097-2107.
PMID: 39078476
Introduction: Bariatric surgery (BS) has emerged an effective intervention in achieving significant and sustained weight loss in patients with type 2 diabetes (T2D). However, comprehensive data on the long-term impact...
2.
Heald A, Jenkins D, Williams R, Mudaliar R, Khan A, Syed A, et al.
Diabetes Ther
. 2023 Oct;
14(12):2043-2044.
PMID: 37796425
No abstract available.
3.
Heald A, Jenkins D, Williams R, Mudaliar R, Khan A, Syed A, et al.
Diabetes Ther
. 2023 Aug;
14(12):2031-2042.
PMID: 37620452
Introduction: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus (coronavirus disease 2019 [COVID-19]) pandemic revealed the vulnerability of specific population groups in relation to susceptibility to acute deterioration in...
4.
Razvi S, Jabbar A, Addison C, Vernazza J, Syed A, Soran H, et al.
Eur J Endocrinol
. 2023 Feb;
188(2).
PMID: 36751726
Many individuals with marginally abnormal thyroid function test (TFT) results may be treated and it is unknown if the limits of the thyrotropin (TSH) and free thyroxine (FT4) reference intervals...
5.
Heald A, Jenkins D, Williams R, Sperrin M, Mudaliar R, Syed A, et al.
Diabetes Ther
. 2022 Apr;
13(5):1037-1051.
PMID: 35416588
Introduction: Research is ongoing to increase our understanding of how much a previous diagnosis of type 2 diabetes mellitus (T2DM) affects someone's risk of becoming seriously unwell following a COVID-19...
6.
Ragavan S, Elhelw O, Majeed W, Kyriacou A, Syed A
Cureus
. 2022 Apr;
14(3):e22751.
PMID: 35371892
Alemtuzumab, a humanized monoclonal antibody used as a disease-modifying treatment in relapsing-remitting multiple sclerosis (RRMS), frequently causes autoimmunity as its principal adverse effect. We describe a typical case of a...
7.
Heald A, Jenkins D, Williams R, Sperrin M, Fachim H, Mudaliar R, et al.
Diabetes Ther
. 2022 Mar;
13(5):1007-1021.
PMID: 35325361
Introduction: Since early 2020 the whole world has been challenged by the SARS-CoV-2 virus and the associated global pandemic (Covid-19). People with diabetes are particularly at high risk of becoming...
8.
Iqbal Z, Bashir B, Adam S, Ho J, Dhage S, Azmi S, et al.
Atherosclerosis
. 2022 Mar;
346:10-17.
PMID: 35247628
Background And Aims: The causal relationship between LDL cholesterol (LDL-C) and the pathogenesis of atherosclerosis is well established. Previous studies have shown that modifications, glycation and oxidation of LDL enhance...
9.
Marouf B, Iqbal Z, Mohamad J, Bashir B, Schofield J, Syed A, et al.
Clin Ther
. 2022 Mar;
44(2):331-348.
PMID: 35246337
Purpose: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are novel drugs that have proven efficacy in improving cardiovascular outcomes. Roles for the PCSK9 molecule in metabolic pathways beyond LDL receptor...
10.
Iqbal Z, Fachim H, Gibson J, Baricevic-Jones I, Campbell A, Geary B, et al.
J Clin Med
. 2021 Aug;
10(16).
PMID: 34441954
Bariatric surgery (BS) results in metabolic pathway recalibration. We have identified potential biomarkers in plasma of people achieving type 2 diabetes mellitus (T2DM) remission after BS. Longitudinal analysis was performed...